CME

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

Overview

Author(s)/Faculty: John M. Kirkwood, MD; Ahmad A. Tarhini, MD, PhD
Source: Healio - Hematology/Oncology Education Lab
Type: LectureArticles/Items: 3
Release Date: 1/25/2017Expiration Date: 1/24/2018
Credit Type: CMENumber of Credits: 1
Cost: FreeProvider: Vindico Medical Education
It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately 10,130 disease-related deaths. Recent advances in the understanding of the underlying biology of melanoma have resulted in the identification of new novel targets for therapy, resulting in significant improvements to clinical outcomes for patients with advanced disease. As these newer agents, specifically immune checkpoint inhibitors, are incorporated into everyday clinical practice, it is imperative that health care professionals who provide care to patients with melanoma are aware of these recent advances. Within the CME activity, Dr. Kirkwood and Dr. Tarhini discuss the efficacy and safety of current and emerging immune checkpoint inhibitors and their impact on clinical outcomes in patients with advanced melanoma.

CME Information

page 1 of 6